Deciphering biology,
discovering new anti-infectives
through deep phenotypic insights and machine learning
The "silent pandemic" is no longer silent.
Antimicrobial resistance (AMR) leading to drug-resistant infections is now a recognized and growing global health crisis. The limited pipeline of new drugs to treat the increase in drug resistant infections is a significant global concern.
New classes of antibiotics are urgently needed to combat the rise of drug resistance.
Learn MoreDiscovering new classes of anti-infectives to overcome drug resistant infections.
Our machine learning (ML)-based imaging platform for anti-infective drug discovery enables rapid and highly efficient identification of compounds with new and unexploited mechanisms of action at the very outset of the discovery process.
Our combined expertise, cutting edge technologies and novel workflows enable a rapid and early understanding of a compound’s mechanism of action, the potential addressable target product profile, and clinical utility based on deep analysis of cell behavior.
Explore PlatformDelivering new classes of anti-infectives.
ArrePath is applying its technology platform to develop a pipeline of new classes of antibiotics,
targeting unexploited and under-exploited mechanisms of action, to address unmet clinical need and overcome drug resistance.
Recent News and Updates
-
Kevin Krause named President and CEO of ArrePath
ArrePath today announced the appointment of Kevin Krause as President and Chief Executive.
11-19-2024 -
ArrePath Secures £1 Million Grant from PACE to Advance Novel Antibiotics Against Multidrug-Resistant Bacterial Infections
ArrePath today announced that it has been awarded a £1 million non-dilutive grant from PACE (Pathways to Antimicrobial Clinical Efficacy) in support of its efforts to develop a new class of antibiotics designed to address multidrug-resistant (MDR) infections, a growing global health threat.
-
BioNJ BioPartnering Conference, May 14, 2024 Liberty Science Center, NJ.
ArrePath will be presenting at the BioNJ BioPartnering event on May 14th at Liberty Science Center in Jersey City, NJ!
Join us in the Delta Lab at 10:50 AM – 12:10 PM.
The BioNJ BioPartnering Conference is co-sponsored by J.P. Morgan, J&J Innovation, and Morgan Lewis, and hosted by the Jersey City Economic Development Corporation.
03-18-2024